Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma

Biomarker-driven targeted therapies have been an area of exploration for innovative therapeutic options in oncology. B-cell lymphoma-2 (BCL-2) protein is an anti-apoptotic protein expressed on the clonal plasma cells in patients with multiple myeloma (MM). MM subsets with t (11;14) have overexpressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehsan, Hamid, Wahab, Ahsan, Shah, Zunairah, Sana, Muhammad Khawar, Masood, Adeel, Rafae, Abdul, Hashmi, Hamza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256917/
https://www.ncbi.nlm.nih.gov/pubmed/34267845
http://dx.doi.org/10.14740/jh844
_version_ 1783718194659196928
author Ehsan, Hamid
Wahab, Ahsan
Shah, Zunairah
Sana, Muhammad Khawar
Masood, Adeel
Rafae, Abdul
Hashmi, Hamza
author_facet Ehsan, Hamid
Wahab, Ahsan
Shah, Zunairah
Sana, Muhammad Khawar
Masood, Adeel
Rafae, Abdul
Hashmi, Hamza
author_sort Ehsan, Hamid
collection PubMed
description Biomarker-driven targeted therapies have been an area of exploration for innovative therapeutic options in oncology. B-cell lymphoma-2 (BCL-2) protein is an anti-apoptotic protein expressed on the clonal plasma cells in patients with multiple myeloma (MM). MM subsets with t (11;14) have overexpression of BCL-2 and can benefit from venetoclax (VEN) when used either alone or in combination with other chemotherapeutic agents with an overall response rate (ORR) ranging from 40% to 100%. The most commonly reported grade ≥ 3 adverse effects include cytopenias and gastrointestinal side effects. This review highlights the meaningful efficacy and tolerable safety of VEN monotherapy and its combination regimens in the treatment of relapsed refractory MM.
format Online
Article
Text
id pubmed-8256917
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-82569172021-07-14 Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma Ehsan, Hamid Wahab, Ahsan Shah, Zunairah Sana, Muhammad Khawar Masood, Adeel Rafae, Abdul Hashmi, Hamza J Hematol Review Biomarker-driven targeted therapies have been an area of exploration for innovative therapeutic options in oncology. B-cell lymphoma-2 (BCL-2) protein is an anti-apoptotic protein expressed on the clonal plasma cells in patients with multiple myeloma (MM). MM subsets with t (11;14) have overexpression of BCL-2 and can benefit from venetoclax (VEN) when used either alone or in combination with other chemotherapeutic agents with an overall response rate (ORR) ranging from 40% to 100%. The most commonly reported grade ≥ 3 adverse effects include cytopenias and gastrointestinal side effects. This review highlights the meaningful efficacy and tolerable safety of VEN monotherapy and its combination regimens in the treatment of relapsed refractory MM. Elmer Press 2021-06 2021-06-16 /pmc/articles/PMC8256917/ /pubmed/34267845 http://dx.doi.org/10.14740/jh844 Text en Copyright 2021, Ehsan et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ehsan, Hamid
Wahab, Ahsan
Shah, Zunairah
Sana, Muhammad Khawar
Masood, Adeel
Rafae, Abdul
Hashmi, Hamza
Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
title Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
title_full Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
title_fullStr Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
title_full_unstemmed Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
title_short Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
title_sort role of venetoclax in the treatment of relapsed and refractory multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256917/
https://www.ncbi.nlm.nih.gov/pubmed/34267845
http://dx.doi.org/10.14740/jh844
work_keys_str_mv AT ehsanhamid roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT wahabahsan roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT shahzunairah roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT sanamuhammadkhawar roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT masoodadeel roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT rafaeabdul roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT hashmihamza roleofvenetoclaxinthetreatmentofrelapsedandrefractorymultiplemyeloma

Ejemplares similares